Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Maria Gomez

Maria Gomez

Professor

Maria Gomez

MicroRNA-dependent regulation of KLF4 by glucose in vascular smooth muscle

Author

  • Tran T. Hien
  • Eliana Garcia-Vaz
  • Karin G. Stenkula
  • Johan Sjögren
  • Johan Nilsson
  • Maria F. Gomez
  • Sebastian Albinsson

Summary, in English

Diabetes is a major risk factor for cardiovascular disease and this is in part due to the effects of hyperglycemia on vascular smooth muscle cells. Small non-coding microRNAs are known to control smooth muscle phenotype and arterial contractility and are dysregulated in diabetes. The effect of microRNAs on smooth muscle differentiation is in part mediated by the transcription factor KLF4 but the role of this mechanism in diabetic vascular disease is not fully understood. Herein, we have investigated the importance of hyperglycemia and diabetes for the expression of KLF4 in vascular smooth muscle and the involvement of miRNAs in this regulation. Hyperglycemia down-regulated KLF4 in vascular smooth muscle cells and similar results were found in arteries of diabetic mice and patients. This correlated with a Foxa2-dependent up-regulation of miR-29c, which targeted KLF4 in vascular smooth muscle cells. Importantly, by preventing downregulation of KLF4, the induction of smooth muscle contractile protein markers by glucose was inhibited. In conclusion, miR-29 mediated inhibition of KLF4 in hyperglycemic conditions contributes to increased expression of contractile markers in vascular smooth muscle cells. Further studies are warranted to determine the therapeutic implications of miR-29 inhibition in diabetic vascular disease.

Department/s

  • Department of Experimental Medical Science
  • Department of Clinical Sciences, Malmö
  • Thoracic Surgery
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2018

Language

English

Pages

7195-7205

Publication/Series

Journal of Cellular Physiology

Volume

233

Issue

9

Document type

Journal article

Publisher

John Wiley and Sons

Topic

  • Cardiac and Cardiovascular Systems
  • Cell and Molecular Biology

Keywords

  • Contractile differentiation
  • Glucose
  • MicroRNA
  • Vascular smooth muscle

Status

Published

ISBN/ISSN/Other

  • ISSN: 0021-9541